声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议。近日,吉利德发布了2024年第三季度业绩:2024年前三季度总营收211.85亿美元,同比增长6%;2024 Q3总营收75.45亿美元,与去年同期相比增长5%,这主要是由于HIV药物(51亿美元,+9%)、Veklury(6.92亿美元,+9%)、肿瘤...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.